Rosiglitazone is a PPARγ synthetic activator from the group of thiazolidinediones (TZDs) often used in the treatment of chronic diseases such as type 2 diabetes and other forms of insulin resistance, as seen in polycystic ovary syndrome (PCOS). Here, PPARG is linked to polycystic ovary syndrome.